Zivo Bioscience, Inc. financial data

Symbol
ZIVO, ZIVOW on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
21 E. Long Lake Road, Suite 100, Bloomfield Hills, MI
State of incorporation
NV
Fiscal year end
December 31
Former names
HEALTH ENHANCEMENT PRODUCTS INC (to 10/16/2014), WESTERN GLORY HOLE INC (to 1/26/2004)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 18.3 % -59.3%
Debt-to-equity -128 % +36.6%
Return On Assets -2.24K % -299%
Operating Margin -17.3K % +65.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.55M shares +94.9%
Common Stock, Shares, Outstanding 3.49M shares +100%
Entity Public Float 17.3M USD -38.9%
Common Stock, Value, Issued 3.49K USD +100%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 79K USD +399%
Revenue from Contract with Customer, Excluding Assessed Tax 79K USD +167%
Research and Development Expense 3.2M USD +102%
General and Administrative Expense 10.5M USD +63.1%
Operating Income (Loss) -13.7M USD -70.7%
Nonoperating Income (Expense) -13.3K USD +88%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -13.7M USD -60.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.8M USD -79.8%
Assets, Current 437K USD -77.6%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 22.3K USD -81.7%
Assets 496K USD -76.4%
Accounts Payable, Current 788K USD +22.3%
Accrued Liabilities, Current 1.13M USD +37.2%
Liabilities, Current 2.58M USD -18.8%
Long-term Debt and Lease Obligation 132K USD
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 2.58M USD -19.3%
Retained Earnings (Accumulated Deficit) -135M USD -11.3%
Stockholders' Equity Attributable to Parent -2.08M USD -90.4%
Liabilities and Equity 496K USD -76.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.7M USD +20.2%
Net Cash Provided by (Used in) Financing Activities 1.56M USD +190%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 25M shares 0%
Common Stock, Shares, Issued 2.38M shares +51.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 159K USD -89.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.06K USD -13.5%
Deferred Tax Assets, Valuation Allowance 12.4M USD +14.7%
Deferred Tax Assets, Gross 10.8M USD +18.7%
Operating Lease, Liability 132K USD -41%
Lessee, Operating Lease, Liability, to be Paid 142K USD
Property, Plant and Equipment, Gross 100K USD 0%
Operating Lease, Liability, Current 22K USD -80%
Lessee, Operating Lease, Liability, to be Paid, Year Two 112K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 29.5K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.47K USD -68.1%
Preferred Stock, Shares Issued 3.49M shares +100%
Additional Paid in Capital 133M USD +10.5%
Deferred Tax Assets, Net of Valuation Allowance 12.4M USD +14.7%
Share-based Payment Arrangement, Expense 571K USD -41.5%
Interest Expense -25.7K USD -136%